<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02234492</url>
  </required_header>
  <id_info>
    <org_study_id>20140263-01H</org_study_id>
    <nct_id>NCT02234492</nct_id>
  </id_info>
  <brief_title>The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients</brief_title>
  <official_title>The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario HIV Treatment Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of rosuvastatin in Human&#xD;
      Immunodeficiency Virus (HIV) infected individuals lowers inflammation in blood vessels,&#xD;
      improves blood circulation in the small arteries that provide nutrients to the heart muscle&#xD;
      and improves neurocognitive function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV is a chronic inflammatory disease. Patients with HIV are at a high risk of cardiovascular&#xD;
      disease (CVD) which may be related to this state of chronic inflammation. HIV infected&#xD;
      individuals are at up to four times higher risk of suffering a heart attack (also know as&#xD;
      acute coronary syndrome).&#xD;
&#xD;
      The medicine rosuvastatin, commonly used to treat high cholesterol, has been shown to reduce&#xD;
      inflammation in arteries in the general population and also in patients with high risk for&#xD;
      heart problems.&#xD;
&#xD;
      72 subjects with HIV infection will be enrolled and divided into 2 groups of 36.&#xD;
&#xD;
      Group 1: Treatment Group: Participants will receive a low dose of rosuvastatin, 10mg, for 6&#xD;
      months in addition to their current medical therapy.&#xD;
&#xD;
      Group 2: Control Group: Participants will not receive rosuvastatin for 6 months and will&#xD;
      continue with their current medical therapy.&#xD;
&#xD;
      Participants in both groups will undergo blood tests, Myocardial Contrast Echocardiography&#xD;
      (MCE) scan and a Positron Emission Tomography/Computed Tomography PET/CT scan using a&#xD;
      radioactive tracer called fluorodeoxyglucose (FDG-PET), monocyte and serum cytokine studies&#xD;
      at baseline and 6 months.&#xD;
&#xD;
      10 subjects without HIV will also be enrolled to undergo monocyte and serum cytokine blood&#xD;
      tests only, for comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between coronary flow reserve (CFR) and maximum target to background ratio (TBRmax).</measure>
    <time_frame>At baseline</time_frame>
    <description>At baseline, correlation between CFR by MCE and vascular inflammation (TBRmax) by FDG-PET/CT will be assessed. We anticipate good overall concurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CFR</measure>
    <time_frame>At 6 months</time_frame>
    <description>Changes in CFR as measured by MCE will be evaluated over six months in HIV+ patients on ART and treated with rosuvastatin versus those not on a statin. Our study will be one of the first to examine the effects of rosuvastatin on measures of both inflammation and CFR in HIV+ patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TBRmax.</measure>
    <time_frame>At 6 months</time_frame>
    <description>Changes in vascular inflammation (TBRmax) as measured by FDG-PET/CT will be evaluated over six months in HIV+ patients on ART and treated with rosuvastatin versus those not on a statin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurocognitive function</measure>
    <time_frame>At 6 months</time_frame>
    <description>Changes in neurocognitve function as measured by a neuropsychological test battery (AMS-III Spatial Span, WAIS-R Digit Symbol, Hopkins Verbal Learning Test, Grooved Pegboard, Trail Making Tests A&amp;B, Letter Numbering Sequencing , Patient's Assessment of Own Functioning, Center for Epidemiologic Studies-Depression Scale) will be evaluated over six months .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <condition>Cardiovascular Disease (CVD)</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 10mg once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No rosuvastatin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No rosuvastatin- this group will continue with their current medical therapy for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Comparison of rosuvastatin to no rosuvastatin</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40-90 years of age&#xD;
&#xD;
          -  documented evidence of HIV infection&#xD;
&#xD;
          -  on standard antiretroviral therapy(ART) for &gt;1 years&#xD;
&#xD;
          -  viral load persistently below the limits of detection while on ART&#xD;
&#xD;
          -  current Cluster of Differentiation Antigen 4 (CD4) count &gt;350 cells/microlitre&#xD;
&#xD;
          -  baseline Framingham risk score of 10-20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled diabetes mellitus (glycated hemoglobin (HbA1C) &gt;6.5% or fasting glucose&#xD;
             &gt;7.0 mmol/L)&#xD;
&#xD;
          -  uncontrolled hypertension (systolic blood pressure &gt;160 or diastolic blood pressure&#xD;
             &gt;90)&#xD;
&#xD;
          -  known coronary artery disease (CAD) e.g. previous myocardial infarction,&#xD;
             revascularization procedure, or history of angina&#xD;
&#xD;
          -  chronic renal failure (glomerular filtration rate (GFR) &lt;60 ml/min)&#xD;
&#xD;
          -  total cholesterol &gt;5.8 mmol/L&#xD;
&#xD;
          -  Low-density lipoprotein (LDL) cholesterol &gt;4.0 mmol/L&#xD;
&#xD;
          -  already receiving a statin for baseline dyslipidemia&#xD;
&#xD;
          -  pregnant or lactating&#xD;
&#xD;
          -  active untreated Hepatitis B or C&#xD;
&#xD;
          -  diagnosis or clinical evidence of a concomitant inï¬‚ammatory/autoimmune disease&#xD;
&#xD;
          -  patients at baseline demonstrating regional perfusion abnormalities (confined to&#xD;
             individual coronary territories) following stress MCE will be excluded and further&#xD;
             management will be according to local best practice guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Dwivedi, MD MRCP PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Ottawa Heart Institute, Harry Perkins Institute of Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Small, MD MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital-General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <last_update_submitted>October 3, 2018</last_update_submitted>
  <last_update_submitted_qc>October 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Gary Small</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology and Clinician Investigator</investigator_title>
  </responsible_party>
  <keyword>Human immunodeficiency virus (HIV)</keyword>
  <keyword>Statin therapy</keyword>
  <keyword>Cardiovascular disease (CVD)</keyword>
  <keyword>Coronary Flow Reserve (CFR)</keyword>
  <keyword>Positron Emission Tomography (PET)</keyword>
  <keyword>Myocardial contrast echocardiography (MCE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

